{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:13:48Z","timestamp":1793643228950,"version":"4.5.1"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Psoriasis is a chronic immune-mediated inflammatory disease whose pathogenesis is a triad of genetic predisposition, immune dysregulation, and environmental triggers. This review provides a novel, in-depth synthesis arguing that microbial dysbiosis is not merely an associative phenomenon but a central regulatory node within this triad, actively shaping immune responses and clinical phenotypes. We move beyond cataloging microbial shifts to construct a detailed mechanistic framework of the gut-skin axis. Gut dysbiosis; characterized by reduced diversity, a diminished Bacteroidetes\/Firmicutes ratio, and depleted SCFA producers, compromises intestinal barrier integrity, reduces systemic immunoregulatory tone via diminished SCFA signaling, and promotes Th17 polarization. This systemic inflammation is directly communicated to the skin. Concurrently, cutaneous dysbiosis, featuring\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    dominance and fungal alterations, disrupts the local barrier, provides chronic antigenic stimulation, and amplifies IL-17-driven inflammation, creating a self-sustaining loop. Crucially, we analyze how specific infections (\n                    <jats:italic>HCV, H. pylori, Streptococcus<\/jats:italic>\n                    ) act as environmental triggers by sharing or activating these very pathways. The bidirectional relationship with therapy is dissected: while biologics induce drug-specific microbiome shifts that often correlate with clinical normalization, they also carry infection risks that must be strategically managed. Emerging microbiome-targeted interventions like specific probiotics show promise but are hampered by methodological inconsistencies. This review uniquely highlights the causality gap and proposes that future breakthroughs require a shift from correlation to mechanism. We conclude that the microbiome is a dynamic interface between genes and environment in psoriasis; its successful integration into diagnostic and therapeutic paradigms demands standardized multi-omics approaches, functional validation, and personalized medicine strategies that target this critical axis.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1714515","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:44:29Z","timestamp":1772779469000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Psoriasis: microbiome dysbiosis and pathogenic mechanisms"],"prefix":"10.3389","volume":"17","author":[{"given":"Binghao","family":"Wang","sequence":"first","affiliation":[{"name":"First Clinical Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13043","DOI":"10.1038\/s41598-021-90684-8","article-title":"Psoriatic disease is associated with systemic inflammation, endothelial activation, and altered haemostatic function","volume":"11","author":"Visser","year":"2021","journal-title":"Sci Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/ptt.S328439","article-title":"The skin microbiome and its role in psoriasis: A review","volume":"13","author":"Celoria","year":"2023","journal-title":"Psoriasis (Auckl)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"8831","DOI":"10.1038\/s41598-024-59603-5","article-title":"Assessing causal relationships between gut microbiota and psoriasis: evidence from two sample Mendelian randomization analysis","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-025-01813-y","article-title":"Unravelling the gut\u2013skin axis: the role of gut microbiota in pathogenesis and management of psoriasis","volume":"33","author":"Pachauri","year":"2025","journal-title":"Inflammopharmacology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12026-020-09149-1","article-title":"The role of Th17 cells in psoriasis","volume":"68","author":"Li","year":"2020","journal-title":"Immunol Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176690","article-title":"Dendritic cells in Parkinson\u2019s disease: Regulatory role and therapeutic potential","volume":"976","author":"Mula","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.3390\/ijms23136955","article-title":"Roles of infection in psoriasis","volume":"23","author":"Zhou","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"12754","DOI":"10.1038\/s41598-020-69537-3","article-title":"Metagenomic analysis of gut microbiota in non-treated plaque psoriasis patients stratified by disease severity: development of a new Psoriasis-Microbiome Index","volume":"10","author":"Dei-Cas","year":"2020","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2022.9188","article-title":"The role of gut microbiome in inflammatory skin disorders: A systematic review","volume":"14","author":"Widhiati","year":"2022","journal-title":"Dermatol Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/pathogens14040358","article-title":"Characterization of the gut microbiota in patients with psoriasis: A systematic review","volume":"14","author":"Gao","year":"2025","journal-title":"Pathogens"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177521","article-title":"Alterations of gut microbiota for the onset and treatment of psoriasis: A systematic review","volume":"998","author":"Xue","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17931","article-title":"Gut microbiota dysbiosis in a cohort of patients with psoriasis","volume":"181","author":"Hidalgo-Cantabrana","year":"2019","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181326","article-title":"Effect of gut involvement in patients with high probability of early spondyloarthritis: data from the DESIR cohort","volume":"47","author":"Wendling","year":"2020","journal-title":"J Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.12788\/cutis.0949","article-title":"Expanding the psoriasis framework: immunopathogenesis and treatment updates","volume":"113","author":"Nong","year":"2024","journal-title":"Cutis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00403-024-03024-x","article-title":"Modulation of the skin and gut microbiome by psoriasis treatment: a comprehensive systematic review","volume":"316","author":"Korneev","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e41672","article-title":"New horizons in the treatment of psoriasis: Modulation of gut microbiome","volume":"11","author":"Memariani","year":"2025","journal-title":"Heliyon"},{"key":"B18","doi-asserted-by":"publisher","first-page":"15528","DOI":"10.1038\/s41598-025-99075-9","article-title":"Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study","volume":"15","author":"Ntawuyamara","year":"2025","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7171\/jbt.20-3102-005","article-title":"Bioinformatics core survey highlights the challenges facing data analysis facilities","volume":"31","author":"Dragon","year":"2020","journal-title":"J Biomol Tech"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1174748","article-title":"Fungal infections among psoriatic patients: etiologic agents, comorbidities, and vulnerable population","volume":"2021","author":"Chadeganipour","year":"2021","journal-title":"Autoimmune Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-024-00434-y","article-title":"Advancing psoriasis care through artificial intelligence: A comprehensive review","volume":"13","author":"Smith","year":"2024","journal-title":"Curr Dermatol Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/1061186x.2024.2347365","article-title":"Roles and therapeutic targeting of dendritic cells in liver fibrosis","volume":"32","author":"Wang","year":"2024","journal-title":"J Drug Target"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.02.016","article-title":"IL-17A promotes psoriasis-associated keratinocyte proliferation through ACT1-dependent activation of YAP-AREG axis","volume":"142","author":"Yu","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxw011","article-title":"IL-17A plays a central role in the expression of psoriasis signature genes through the induction of I\u03baB-\u03b6 in keratinocytes","volume":"28","author":"Muromoto","year":"2016","journal-title":"Int Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188253","article-title":"The central inflammatory regulator I\u03baB\u03b6: induction, regulation and physiological functions","volume":"14","author":"Feng","year":"2023","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.09.029","article-title":"IkappaBzeta is a key player in the antipsoriatic effects of secukinumab","volume":"145","author":"Bertelsen","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.07.036","article-title":"Anti-TNF-\u03b1 monoclonal antibody reverses psoriasis through dual inhibition of inflammation and angiogenesis","volume":"28","author":"Liu","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.16.05427-4","article-title":"Biomolecular index of therapeutic efficacy in psoriasis treated with anti-TNF-alpha agents","volume":"153","author":"Bianchi","year":"2018","journal-title":"G Ital Dermatol Venereol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jab.2017.05.003","article-title":"The role of keratinocytes in inflammation","volume":"15","author":"Jur\u00e1\u0148ov\u00e1","year":"2017","journal-title":"J Appl Biomed"},{"key":"B30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/ptt.S327310","article-title":"Updated perspectives on keratinocytes and psoriasis: keratinocytes are more than innocent bystanders","volume":"12","author":"Ortiz-Lopez","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jid.2020.07.027","article-title":"An autocrine circuit of IL-33 in keratinocytes is involved in the progression of psoriasis","volume":"141","author":"Zeng","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1533335","article-title":"IL-33\/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential","volume":"16","author":"Sheng","year":"2025","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"9825","DOI":"10.1038\/s41598-023-36642-y","article-title":"Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction","volume":"13","author":"England","year":"2023","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9602362","article-title":"Prevalence and possible role of candida species in patients with psoriasis: A systematic review and meta-analysis","volume":"2018","author":"Pietrzak","year":"2018","journal-title":"Mediators Inflammation"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-019-00423-z","article-title":"HLA correlations with clinical phenotypes and risk of metabolic comorbidities in Singapore Chinese psoriasis patients","volume":"23","author":"Shen","year":"2019","journal-title":"Mol Diagn Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2018.09.002","article-title":"Loss-of-function mutations in caspase recruitment domain-containing protein 14 (CARD14) are associated with a severe variant of atopic dermatitis","volume":"143","author":"Peled","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.968935","article-title":"Genome-wide association analysis of anti-TNF-\u03b1 treatment response in Chinese patients with psoriasis","volume":"13","author":"Ren","year":"2022","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2012.05.011","article-title":"Oral Candida colonization and candidiasis in patients with psoriasis","volume":"114","author":"Bedair","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/odi.14422","article-title":"Oral Candida and psoriasis: Is there association? A systematic review and trial sequential analysis","volume":"29","author":"Patini","year":"2023","journal-title":"Oral Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jdermsci.2021.03.006","article-title":"Large-scale plasma-metabolome analysis identifies potential biomarkers of psoriasis and its clinical subtypes","volume":"102","author":"Kishikawa","year":"2021","journal-title":"J Dermatol Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6649","DOI":"10.3390\/ijms25126649","article-title":"Correlations between gut microbiota and hematological, inflammatory, biochemical and oxidative stress parameters in treatment-naive psoriasis patients","volume":"25","author":"Cozma","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jaad.2016.07.039","article-title":"Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries","volume":"76","author":"Garcia-Doval","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/dhps.S28801","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","author":"Ali","year":"2013","journal-title":"Drug Healthc Patient Saf"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41559-018-0519-1","article-title":"Function and functional redundancy in microbial systems","volume":"2","author":"Louca","year":"2018","journal-title":"Nat Ecol Evol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/microorganisms11061420","article-title":"Oral and topical probiotics and postbiotics in skincare and dermatological therapy: A concise review","volume":"11","author":"De Almeida","year":"2023","journal-title":"Microorganisms"},{"key":"B46","doi-asserted-by":"publisher","first-page":"11225","DOI":"10.3390\/ijms241311225","article-title":"Transforming psoriasis care: probiotics and prebiotics as novel therapeutic approaches","volume":"24","author":"Buha\u015f","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e019231","DOI":"10.1136\/bmjopen-2017-019231","article-title":"Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial","volume":"8","author":"Kragsnaes","year":"2018","journal-title":"BMJ Open"},{"key":"B48","doi-asserted-by":"publisher","first-page":"10583","DOI":"10.3390\/ijms251910583","article-title":"Comparative analysis of the cutaneous microbiome in psoriasis patients and healthy individuals-insights into microbial dysbiosis: final results","volume":"25","author":"Radaschin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-016-2647-3","article-title":"A systematic review and meta-analysis on Staphylococcus aureus carriage in psoriasis, acne and rosacea","volume":"35","author":"Totte","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17989","article-title":"Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis","volume":"181","author":"Langan","year":"2019","journal-title":"Br J Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.024","article-title":"Psoriatic lesions are characterized by higher bacterial load and imbalance between Cutibacterium and Corynebacterium","volume":"82","author":"Quan","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2021.06.018","article-title":"Keratin 17 in psoriasis: Current understanding and future perspectives","volume":"128","author":"Lin","year":"2022","journal-title":"Semin Cell Dev Biol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e13986","DOI":"10.1111\/dth.13986","article-title":"Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review","volume":"33","author":"Seirafianpour","year":"2020","journal-title":"Dermatol Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e42791","DOI":"10.7759\/cureus.42791","article-title":"Paradoxical tumor necrosis factor-alpha (TNF-alpha) inhibitor-induced psoriasis: A systematic review of pathogenesis, clinical presentation, and treatment","volume":"15","author":"Chokshi","year":"2023","journal-title":"Cureus"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e13822","DOI":"10.1111\/srt.13822","article-title":"Metagenomics reveals unique gut mycobiome biomarkers in psoriasis","volume":"30","author":"Wang","year":"2024","journal-title":"Skin Res Technol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3390\/ijms22041519","article-title":"Interplay between Humoral and CLA(+) T Cell Response against Candida albicans in Psoriasis","volume":"22","author":"de Jesus-Gil","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s13555-022-00687-0","article-title":"A practical guide to the management of oral candidiasis in patients with plaque psoriasis receiving treatments that target interleukin-17","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"857\u201369, e857","DOI":"10.1016\/j.jaci.2021.01.006","article-title":"Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies","volume":"147","author":"Patrick","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e14204","DOI":"10.1111\/dth.14204","article-title":"Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic","volume":"33","author":"Giuliani","year":"2020","journal-title":"Dermatol Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/biom15010046","article-title":"Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial","volume":"15","author":"Petkovic-Dabic","year":"2025","journal-title":"Biomolecules"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2015.07.017","article-title":"The IL-33\/ST2 axis: Role in health and disease","volume":"26","author":"De la Fuente","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1159\/000511622","article-title":"Dysbiosis of oral microbiota associated with palmoplantar pustulosis","volume":"237","author":"Kageyama","year":"2021","journal-title":"Dermatology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00849-7","article-title":"Gut microbiome in psoriasis is perturbed differently during secukinumab and ustekinumab therapy and associated with response to treatment","volume":"39","author":"Yeh","year":"2019","journal-title":"Clin Drug Investig"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad252","article-title":"Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)","volume":"189","author":"Stein Gold","year":"2023","journal-title":"Br J Dermatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15653","article-title":"Safety of selective IL-23p19 inhibitors for the treatment of psoriasis","volume":"33","author":"Crowley","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12281-010-0001-2","article-title":"Tumor necrosis factor inhibitors and fungal infections","volume":"4","author":"Smith","year":"2010","journal-title":"Curr Fungal Infect Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15156","article-title":"Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: Real-world data from 18 Japanese facilities","volume":"47","author":"Kaneko","year":"2020","journal-title":"J Dermatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/v17010042","article-title":"Incidence of HBV reactivation in psoriasis patients undergoing cytokine inhibitor therapy: A single-center study and systematic review with a meta-analysis","volume":"17","author":"Kuo","year":"2024","journal-title":"Viruses"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.03.1501","article-title":"Longitudinal study of the psoriasis-associated skin microbiome during therapy with ustekinumab in a randomized phase 3b clinical trial","volume":"138","author":"Loesche","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1801976","article-title":"Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit","volume":"33","author":"Lanna","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13397","article-title":"The Vitamin D3 analogue calcipotriol suppresses CpG-activated TLR9-MyD88 signalling in murine plasmacytoid dendritic cells","volume":"43","author":"Suzuki","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3305","article-title":"Efficacy and safety of oral administration of a mixture of probiotic strains in patients with psoriasis: A randomized controlled clinical trial","volume":"99","author":"Navarro-Lopez","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219511","article-title":"Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial","volume":"80","author":"Kragsnaes","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B75","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/sji.12304","article-title":"The vitamin D analogue calcipotriol reduces the frequency of CD8+ IL-17+ T cells in psoriasis lesions","volume":"82","author":"Dyring-Andersen","year":"2015","journal-title":"Scand J Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0357","article-title":"Effect of vitamin D supplementation on psoriasis severity in patients with lower-range serum 25-hydroxyvitamin D levels: A randomized clinical trial","volume":"159","author":"Jenssen","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/ced\/llad329","article-title":"Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies","volume":"49","author":"Lebwohl","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e0242098","DOI":"10.1371\/journal.pone.0242098","article-title":"TST conversions and systemic interferon-gamma increase after methotrexate introduction in psoriasis patients","volume":"15","author":"de Medeiros","year":"2020","journal-title":"PloS One"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2372895","article-title":"A randomized, double-blind, controlled clinical study on the curative effect of huaier on mild-to-moderate psoriasis and an experimental study on the proliferation of hacat cells","volume":"2018","author":"Su","year":"2018","journal-title":"BioMed Res Int"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17691","article-title":"Investigation of the skin microbiome: swabs vs. biopsies","volume":"181","author":"Prast-Nielsen","year":"2019","journal-title":"Br J Dermatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05169-2","article-title":"Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study","volume":"43","author":"Capkin","year":"2023","journal-title":"Rheumatol Int"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111904","article-title":"The influence of biologics on the microbiome in immune-mediated inflammatory diseases: A systematic review","volume":"141","author":"Ruszkowski","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"B83","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1744666x.2023.2250918","article-title":"Durability and long-term outcomes of biologic therapies in psoriasis","volume":"20","author":"Rusi\u00f1ol","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ptt.S328575","article-title":"Biologics in psoriasis: updated perspectives on long-term safety and risk management","volume":"12","author":"Al-Janabi","year":"2022","journal-title":"Psoriasis (Auckl)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1714515\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:44:40Z","timestamp":1772779480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1714515\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":84,"alternative-id":["10.3389\/fimmu.2026.1714515"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1714515","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"article-number":"1714515"}}